Among patients with relapsing multiple sclerosis, 450 mg of ublituximab could be safely infused in 30 minutes at week 24.

Efficacy of treatment is maintained during the switch from IV anti-CD20 therapies to ofatumumab in relapsing MS regardless of race/ethnicity.

Ocrelizumab treatment in Black and Hispanic patients with MS reduces NfL levels and prevents the forming of contrast-enhancing lesions and new or enlarging T2 lesions.

Sexual dysfunction and depression are common and associated with increased disability in patients with multiple sclerosis.

Higher ocrelizumab doses improve the benefit-risk profile among patients with relapsing multiple sclerosis treated with it for up to 10 years.

The risk of developing MS and other demyelinating diseases is 3 times greater in individuals diagnosed with EBV-positive IM.

There is an inverse bidirectional association between cancer and dementia, a relationship that holds across cancer and dementia subtypes.

The US Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for people living with spinal muscular atrophy (SMA).

Women with epilepsy may have offspring with decreased bone metabolism and lower birth weight, according to a study.

Psychiatric comorbidities in epilepsy, such as anxiety, depression, and psychotic disorders, are more common in patients with vs those without it.

Greater prenatal and early childhood sun exposure is associated with a lower risk for relapse among children with multiple sclerosis (MS).

Discontinuation of first-line DMTs among patients with stable MS for at least 5 years may lead to an increased risk for recurrence.